Elanco Animal Health (NYSE:ELAN – Get Free Report) had its price objective boosted by UBS Group from $31.00 to $33.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 49.61% from the stock’s previous close.
ELAN has been the subject of several other research reports. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Morgan Stanley increased their price target on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 22nd. JPMorgan Chase & Co. raised their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Citigroup increased their price target on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, TD Cowen upped their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus target price of $29.09.
View Our Latest Stock Analysis on Elanco Animal Health
Elanco Animal Health Stock Down 8.9%
Elanco Animal Health (NYSE:ELAN – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities analysts expect that Elanco Animal Health will post 1.12 earnings per share for the current year.
Insider Buying and Selling at Elanco Animal Health
In other news, insider Rajeev A. Modi purchased 4,911 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the transaction, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The shares were purchased at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the transaction, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is currently owned by corporate insiders.
Institutional Trading of Elanco Animal Health
A number of institutional investors have recently modified their holdings of the company. NewEdge Advisors LLC grew its stake in shares of Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after acquiring an additional 627 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Elanco Animal Health during the 2nd quarter worth about $38,000. Root Financial Partners LLC grew its holdings in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after acquiring an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new position in shares of Elanco Animal Health in the 4th quarter valued at about $41,000. Finally, Torren Management LLC acquired a new stake in shares of Elanco Animal Health in the fourth quarter valued at about $46,000. 97.48% of the stock is currently owned by institutional investors.
Elanco Animal Health Company Profile
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.
Featured Stories
- Five stocks we like better than Elanco Animal Health
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
